stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue.

Able and willing to give written informed consent and has signed the informed consent form (ICF), prior to performance of any trial activities.

Eligible male and female subjects aged 18-75 years.

Lung function capacity capable of tolerating the proposed lung surgery.

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

Available tissue of primary lung tumor.

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)